摘要
目的探讨重组人脑利钠肽对慢性心力衰竭(心衰)患者心功能和心肌损伤的影响。方法 70例慢性心衰患者,随机分为重组人脑利钠肽组(36例)和对照组(34例)。对照组采用常规抗心衰药物治疗,重组人脑利钠肽组在对照组基础上加用重组人脑利钠肽治疗。治疗后评价两组临床疗效,并于治疗前后检测两组心肌肌钙蛋白T(cTnT)、N末端脑钠肽前体(NT-proBNP)水平以及左室射血分数(LVEF)、每搏心输出量(SV)、左室收缩末期内径(LVESD)。结果经过48 h治疗后,重组人脑利钠肽组总有效率为91.67%,对照组总有效率为70.59%,比较差异有统计学意义(P<0.05)。经过治疗后,两组患者cTnT及NT-proBNP水平均较治疗前降低,差异有统计学意义(P<0.05)。重组人脑利钠肽组cTnT及NT-proBNP水平较对照组下降明显,差异有统计学意义(P<0.05)。经过治疗后,两组患者的LVEF及SV水平较治疗前均有所增加,差异有统计学意义(P<0.05)。重组人脑利钠肽组SV为(76.32±15.37)ml,较对照组的(65.45±13.58)ml明显增加,差异有统计学意义(P<0.05)。结论在传统药物基础上加用重组人脑利钠肽治疗慢性心衰患者能够显著改善心脏收缩能力,减轻心肌损伤,疗效显著,值得积极推广。
Objective To investigate influence by recombinant human brain natriuretic peptide on cardiac function and myocardial damage in chronic heart failure patients.Methods A total of70patients with chronic heart failure were randomly divided into recombinant human brain natriuretic peptide group(36cases)and control group(34cases).The control group received conventional cardiotonic drug therapy,and the recombinant human brain natriuretic peptide group received additional recombinant human brain natriuretic peptide to drug therapy in the control group.Clinical effects in the two groups were evaluated after treatment.Detection was made on cardiac troponin T(cTnT),N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular ejection fraction(LVEF),stroke volume(SV)and left ventricular end systolic diameter(LVESD)in the two groups before and after treatment.Results After48-h treatment,the recombinant human brain natriuretic peptide group had total effective rate as91.67%,and the control group had total effective rate as70.59%.The difference had statistical significance between the two groups(P<0.05).After treatment,both groups had lower cTnT and NT-proBNP levels than those before treatment,and their difference had statistical significance(P<0.05).The recombinant human brain natriuretic peptide group had more obvious reduction in cTnT and NT-proBNP levels than the control group,and the difference had statistical significance(P<0.05).After treatment,both groups had higher LVEF and SV levels than those before treatment,and the difference had statistical significance(P<0.05).The recombinant human brain natriuretic peptide group had obviously higher SV as(76.32±15.37)ml than(65.45±13.58)ml in the control group,and the difference had statistical significance(P<0.05).Conclusion Additional implement of recombinant human brain natriuretic peptide to traditional drug therapy in treating patients with chronic heart failure can remarkably improve systolic function and relieve myocardial damage,along with excellent curative effect.This method is worth active promotion.
作者
杨光全
YANG Guang-quan(Department of Cardiology, Heze Municipal Hospital, Heze 274000, China)
出处
《中国现代药物应用》
2017年第8期4-6,共3页
Chinese Journal of Modern Drug Application
关键词
重组人脑利钠肽
慢性心力衰竭
心肌肌钙蛋白T
N末端脑钠肽前体
Recombinant human brain natriuretic peptide
Chronic heart failure
Cardiac troponin T
N-terminal pro-brain natriuretic peptide
